Get started
Author

Yvonne Grobben

Observed names: Grobben, Yvonne, Y. Grobben
ORCID: 0000-0002-3460-3593
Observed ORCID: 0000-0002-3460-3593
OpenAlex ID: A5068578739
Structural insights into human Arginase-1 pH dependence and its inhibition by the small molecule inhibitor CB-1158
2019 · Yvonne Grobben, Joost C.M. Uitdehaag, et al. · Journal of Structural Biology X · 40
PDF
Targeting amino acid-metabolizing enzymes for cancer immunotherapy
2024 · Yvonne Grobben · Frontiers in Immunology · 30
Pharmacological validation of TDO as a target for Parkinson’s disease
2021 · Paula Perez‐Pardo, Yvonne Grobben, et al. · FEBS Journal · 30
PDF
Amino Acid-Metabolizing Enzymes in Advanced High-Grade Serous Ovarian Cancer Patients: Value of Ascites as Biomarker Source and Role for IL4I1 and IDO1
2023 · Yvonne Grobben, Judith E. den Ouden, et al. · Cancers · 22
PDF
Comparative kinase and cancer cell panel profiling of kinase inhibitors approved for clinical use from 2018 to 2020
2022 · Jeffrey J. Kooijman, Wilhelmina E. van Riel, et al. · Frontiers in Oncology · 22
Targeting Indoleamine 2,3-Dioxygenase in Cancer Models Using the Novel Small Molecule Inhibitor NTRC 3883-0
2021 · Yvonne Grobben, Jos de Man, et al. · Frontiers in Immunology · 18
PDF
Installation of Trimethyllysine Analogs on Intact Histones via Cysteine Alkylation
2019 · Bas J. G. E. Pieters, Jordi C. J. Hintzen, et al. · Bioconjugate Chemistry · 18
Chemotherapy sensitivity testing on ovarian cancer cells isolated from malignant ascites
2020 · Judith E. den Ouden, Guido J.R. Zaman, et al. · Oncotarget · 12
PDF
High-Throughput Fluorescence-Based Activity Assay for Arginase-1
2020 · Yvonne Grobben, Nicole Willemsen-Seegers, et al. · SLAS DISCOVERY · 12
Abstract 4668: Characterization of fourth-generation EGFR inhibitors in binding experiments with C797S mutant EGFR and cell-based assays with osimertinib-resistant non-small cell lung cancer cell lines
2024 · Janneke J. Melis, Kirsten Kevenaar, et al. · Cancer Research · 3
Combined cellular and biochemical profiling of Bruton’s tyrosine kinase inhibitor nemtabrutinib reveals potential application in MAPK-driven cancers
2025 · Daphne J. F. Kluitmans, Janneke J. T. M. Melis, et al. · Frontiers in Oncology · 1
PDF
Author response for "Pharmacological validation of TDO as a target for Parkinson’s disease"
2020 · Paula Perez‐Pardo, Yvonne Grobben, et al. · 1
Comparative profiling of osimertinib and fourth-generation EGFR inhibitors on EGFR-mutant proteins and cell lines
2026 · Janneke J. T. M. Melis, Kirsten J. W. Kevenaar, et al. · Frontiers in Oncology
PDF
Abstract 1879: Characterization of intrinsic and acquired resistance to KRASG12C inhibitors across a broad collection of cancer cell line models.
2026 · Jeffrey J. Kooijman, Kirsten J. Kevenaar, et al. · Cancer Research
Synthesis and Absolute Configuration of the Sesquiterpene Lactone EPD, a Natural Product with Broad Antitumor Cell Activity via a Unique Mechanism of Action
2025 · Caroline van Haaften, Jan Koek, et al. · Journal of Natural Products
PDF
Abstract 6961: Characterization of EGFR C797S-mutant, osimertinib-resistant non-small cell lung cancer cells
2025 · Janneke J. Melis, Kirsten J. Kevenaar, et al. · Cancer Research
73P Combined cellular and biochemical profiling of BTK inhibitor nemtabrutinib reveals potential application in MAPK pathway-driven cancers
2025 · G. Zaman, J. Melis, et al. · ESMO Open
262 (PB250): High-throughput fluorescence-based screening assay for indoleamine 2,3-dioxygenase 2 (IDO2)
2024 · N. Willemsen-Seegers, S. van der Leeuw, et al. · European Journal of Cancer
Abstract 7126: Synergistic combinations and tissue type-specificity of compounds targeting components of the DNA damage response pathway in 2D culture and 3D spheroid cell viability assays
2024 · Janneke J. Melis, Daphne J. Kluitmans, et al. · Cancer Research
Targeting amino acid-metabolizing enzymes for cancer immunotherapy and treatment of Parkinson’s disease
2023 · Yvonne Grobben
Abstract 2865: IL4I1, IDO1 and other amino acid-metabolizing enzymes in high-grade serous ovarian cancer
2023 · Yvonne Grobben, Judith E. den Ouden, et al. · Cancer Research
30P Comparative biochemical and cellular profiling of kinase inhibitors approved for clinical use from 2018 to 2020
2022 · J. Kooijman, W. Van Riel, et al. · Annals of Oncology
Abstract 1480: Comparative cancer cell panel profiling of kinase inhibitors approved for clinical use from 2018 to 2020
2021 · Jeffrey J. Kooijman, Wilhelmina E. van Riel, et al. · Cancer Research
Abstract B060: Side-by-side comparison of small molecule IDO1 inhibitors in biochemical and cell-based assays and development of a IDO1-expressing mouse model to evaluate target modulation
2019 · Yvonne Grobben, Joost C.M. Uitdehaag, et al. · Molecular Cancer Therapeutics
Crystal structure of human Arginase-1 at pH 9.0 in complex with CB-1158/INCB001158
2018 · Y. Grobben, J.C.M. Uitdehaag, et al. · Worldwide Protein Data Bank
Works count: 31
Citation count: 209
H-index: 9
I10-index: 9
Year
Topic
Type